- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Introducing Onduo: Sanofi and Verily's Joint Diabetes Venture
If you need further proof that pharma is going high tech, look no further than the partnership between Sanofi, a French drug manufacturer, and Verily, the life science division of Alphabet. The two companies announced Onduo today, a US$500 million venture that will focus on developing new drugs and innovative software to manage diabetes.
If you need further proof that pharma is going high tech, look no further than the partnership between Sanofi (NYSE:SNY, EPA:SAN), a French drug manufacturer, and Verily, the life science division of Alphabet (NASDAQ:GOOG). The two companies announced Onduo today, a US$500 million venture that will focus on developing new drugs and innovative software to manage diabetes.
“Onduo’s mission is to help people with diabetes live full, healthy lives by developing comprehensive solutions that combine devices, software, medicine and professional care to enable simple and intelligent disease management,” the companies said in a joint press release today.
Sanofi, of course, is already a leading manufacturer of diabetes drugs. But according to Venture Beat, that division has weakened recently due to pricing pressures from American competitors. It’s hoped that Onduo, in which Sanofi holds a fifty percent stake, will stimulate this part of the business.
Verily, meanwhile, is well-versed in consumer software and miniaturized electronic devices—after all, it belongs to Alphabet, Google’s parent. It’s also been in the news recently because of another partnership: Verily joined forces with GlaxoSmithKline (NYSE:GSK) in August with plans to work in bioelectronics.
Together, Sanofi and Verily hope to develop products like insulin pens that connect to online data services, a spokesperson told Reuters. The goal is to assist patients with day-to-day management of the disease.
The venture has already received approval from Taking Control of Your Diabetes, a patient advocacy group. Founder and Director Steven V. Edelman lauded Onduo for considering patient care “through the marriage of technology and medicine,” which he said enables those living with diabetes to take control of their own health.
Onduo will focus on type 2 diabetes to start, with plans to consider solutions for type 1 in later years. Eventually, Onduo hopes to develop preventative measures for those at risk of developing the disease.
Considering projections from the International Diabetes Federation—642 million people will have diabetes by 2040—the market for such solutions could be huge in coming years.
Don’t forget to follow us@INN_LifeScience for real-time news updates.
Securities Disclosure: I, Chelsea Pratt, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.